ArticleOncotarget2014
CDKL2 promotes epithelial-mesenchymal transition and breast cancer progression.
Article in Oncotarget, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 47 citations in OpenAlex.
- Prognostic Significance ofMedicina (Kaunas, Lithuania) · 2026Article
- Splicing to keep splicing: A feedback system for cellular homeostasis and state transition.Clinical and translational medicine · 2025Review
- A phylogenetic analysis of the CDKL protein family unravels its evolutionary history and supports theFrontiers in cell and developmental biology · 2025Article
- Discovery and Characterization of a Chemical Probe for Cyclin-Dependent Kinase-Like 2.ACS medicinal chemistry letters · 2024Article
- Discovery and Characterization of a Chemical Probe for Cyclin-Dependent Kinase-Like 2.bioRxiv : the preprint server for biology · 2024Article
- A Narrative Review on CD44's Role in Glioblastoma Invasion, Proliferation, and Tumor Recurrence.Cancers · 2023Review
- The early-stage triple-negative breast cancer landscape derives a novel prognostic signature and therapeutic target.Breast cancer research and treatment · 2022Article
- Muscle transcriptome provides the first insight into the dynamics of gene expression with progression of age in sheep.Scientific reports · 2021Article
- CKB inhibits epithelial-mesenchymal transition and prostate cancer progression by sequestering and inhibiting AKT activation.Neoplasia (New York, N.Y.) · 2021Article
- A novel lncRNA derived from an ultraconserved region: lnc-RNA biology · 2021Article
- Hinge Binder Scaffold Hopping Identifies Potent Calcium/Calmodulin-Dependent Protein Kinase Kinase 2 (CAMKK2) Inhibitor Chemotypes.Journal of medicinal chemistry · 2021Article
- Article
- DecreasedFrontiers in molecular biosciences · 2021Article
- Differentially expressed genes on the growth of mouse Leydig cells treated with standardised Eurycoma longifolia extract.Molecular medicine reports · 2020Article
- Biological roles of Yin Yang 2: Its implications in physiological and pathological events.Journal of cellular and molecular medicine · 2020Review
- Oncogenic functions of the EMT-related transcription factor ZEB1 in breast cancer.Journal of translational medicine · 2020Review
- In Depth Analysis of Kinase Cross Screening Data to Identify CAMKK2 Inhibitory Scaffolds.Molecules (Basel, Switzerland) · 2020Article
- CDKL2 Is Associated with HER2 Status and Overall Survival in Gastric Cancer: Comparative Analysis of CDKL2 Protein Expression and Gene Copy Number.BioMed research international · 2020Article
- Identification of a Set of Genes Improving Survival Prediction in Kidney Renal Clear Cell Carcinoma through Integrative Reanalysis of Transcriptomic Data.Disease markers · 2020Article
- MicroRNA-200c Nanoparticles Sensitized Gastric Cancer Cells to Radiotherapy by Regulating PD-L1 Expression and EMT.Cancer management and research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The epithelial-mesenchymal transition (EMT) confers mesenchymal properties on epithelial cells and has been closely associated with the acquisition of aggressive traits by epithelial cancer cells. To identify novel regulators of EMT, we carried out cDNA screens that covered 500 human kinases. Subsequent characterization of candidate kinases led us to uncover cyclin-dependent kinase-like 2 (CDKL2) as a novel potent promoter for EMT and breast cancer progression. CDKL2-expressing human mammary gland epithelial cells displayed enhanced mesenchymal traits and stem cell-like phenotypes, which was acquired through activating a ZEB1/E-cadherin/β-catenin positive feedback loop and regulating CD44 mRNA alternative splicing to promote conversion of CD24(high) cells to CD44(high) cells. Furthermore, CDKL2 enhanced primary tumor formation and metastasis in a breast cancer xenograft model. Notably, CDKL2 is expressed significantly higher in mesenchymal human breast cancer cell lines than in epithelial lines, and its over-expression/amplification in human breast cancers is associated with shorter disease-free survival. Taken together, our study uncovered a major role for CDKL2 in promoting EMT and breast cancer progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.